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The reticulon (RTN) family of proteins in mam-
mals is composed of four members, RTN-1,   
-2, -3, and -4, which have been characterized   
by the presence of a highly conserved RTN   
homology domain in their C-terminal end, 
which is thought to be important for their lo-
calization in the ER (Oertle and Schwab, 2003; 
Woolf, 2003). While in the ER, RTNs are pos-
tulated to serve fundamental cell-autonomous 
roles in shaping and structuring ER mem-
branes; however, because yeast and mice lacking 
various RTNs are viable, they are not essential 
for cell survival, possibly because of compen-
satory mechanisms to preserve ER integrity 
(Voeltz et al., 2006; Shibata et al., 2008). Recent 
studies have shown functions for RTNs under 
conditions of stress or injury, suggesting that 
they exert permissive roles to enhance or re-
duce stressful insults (Teng and Tang, 2008). 
Evidence for this has been elucidated for RTN-
4A and RTN-4B (also called Nogo-A and –B), 
the most well studied of the mammalian RTN 
family of proteins (Chen et al., 2000; GrandPré 
et al., 2000; Prinjha et al., 2000; Acevedo et al., 
2004;  Fontoura  et  al.,  2004;  Rodriguez-Feo   
et al., 2007; Kritz et al., 2008; Yu et al., 2009).
RTN-4 or the Nogo family is encoded by a 
single gene with three major isoforms, Nogo-A,   
-B, and -C, which are generated by alternative 
splicing for Nogo-A and -B and by alternative 
promoter  utilization  for  Nogo-C  (Oertle  and 
Schwab, 2003). Nogo-A and -C are primarily dis-
tributed in the CNS, with Nogo-C additionally 
expressed in skeletal muscle, whereas Nogo-B is 
more ubiquitously expressed in a variety of tissues 
and cells in culture (Oertle and Schwab, 2003). 
Nogo-A, the largest of the Nogo isoforms, was 
first identified as a myelin-associated inhibitor of 
axon regeneration and neurite outgrowth after 
CNS injury (Chen et al., 2000; GrandPré et al., 
2000; Prinjha et al., 2000). Other studies have 
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Nogo-B is a member of the reticulon family of proteins (RTN-4B) that is highly expressed 
in lung tissue; however, its function remains unknown. We show that mice with Th2-driven 
lung inflammation results in a loss of Nogo expression in airway epithelium and smooth 
muscle compared with nonallergic mice, a finding which is replicated in severe human 
asthma. Mice lacking Nogo-A/B (Nogo-KO) display an exaggerated asthma-like phenotype, 
and epithelial reconstitution of Nogo-B in transgenic mice blunts Th2-mediated lung 
inflammation. Microarray analysis of lungs from Nogo-KO mice reveals a marked reduction 
in palate lung and nasal clone (PLUNC) gene expression, and the levels of PLUNC are en-
hanced in epithelial Nogo-B transgenic mice. Finally, transgenic expression of PLUNC into 
Nogo-KO mice rescues the enhanced asthmatic-like responsiveness in these KO mice. These 
data identify Nogo-B as a novel protective gene expressed in lung epithelia, and its expres-
sion regulates the levels of the antibacterial antiinflammatory protein PLUNC.
© 2010 Wright et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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of antigen-driven Th2-dependent acute allergic inflammation 
that generates an asthma-like response in mice (Wang et al., 
2000). Initially, changes in total lung Nogo-B protein were 
evaluated by comparing levels in control versus allergic lungs 
in WT mice sensitized with OVA plus alum and subsequently 
challenged with aerosolized OVA (allergic mice) or PBS only 
(nonallergic mice). Allergic mice developed a modest decrease 
in total lung Nogo-B protein levels as compared with non-
allergic mice (Fig. 2 A). Both PBS treatment and OVA chal-
lenge without prior sensitization or, conversely, sensitization 
without aerosolized OVA challenge did not induce Nogo-A 
or alter Nogo-B protein levels (Fig. S1). Next, alterations in 
cell type–specific Nogo protein levels were evaluated in WT 
mice via immunostaining with a Nogo-A/B antibody. Inter-
estingly, the levels of immunoreactive Nogo protein decreased 
in airway epithelial and smooth muscle cells in allergic lungs 
(Fig. 2 B, c and d, arrowheads) but remained in vessels (Fig. 2 B, 
b–d, asterisks), whereas Nogo levels were unchanged in non-
allergic lungs (Fig. 2 B, a and b, arrowheads). Quantification 
of immunoreactive Nogo levels demonstrated a marked re-
duction in the epithelium and smooth muscle of the airways 
in allergic lungs (Fig. 2 B, graphs). To address whether the loss 
of Nogo reflected changes in integrity of the epithelial layer 
(such as sloughing of the epithelium) or in epithelial mor-
phogenesis (such as goblet cell hyperplasia), serial sections of 
airways were stained, respectively, with E-cadherin to delin-
eate the epithelium lining or periodic acid-Shiff (PAS) which 
stains for mucus (Fig. 2 B, e and f, and i and j, respectively). 
However, there was no correlation between decreases in Nogo 
levels, compromised integrity of the epithelium, or mor-
phological changes. To determine if changes in Nogo levels in 
asthma-like mouse lungs extrapolates to human tissue, we evalu-
ated immunoreactive Nogo levels in normal and fatal asthmatic 
lung specimens. Immunoreactive Nogo was present at high 
levels throughout the lung, with particular expression noted 
in the airway epithelium, smooth muscle, and vasculature   
(Fig. 2 C, a and c). Similar to findings in the mouse, there was 
a marked reduction in Nogo levels in epithelium and smooth 
muscle of asthmatic specimens (Fig. 2 C, b and d, arrowheads). 
These results were repeated in an additional normal specimen 
and three additional asthmatic specimens (Fig. S2).
To explore whether the reduction in Nogo protein levels 
in large and moderate airway epithelia and smooth muscle 
was a result of changes in Nogo gene expression, Nogo-A/B 
LacZ gene reporter mice were OVA sensitized and challenged 
and lung sections were stained with X-gal. OVA challenge 
reduces Nogo gene expression in airway epithelium that 
mimics the protein changes observed in allergic lungs (Fig. 2 D). 
In contrast, Nogo gene expression is enhanced in the vascula-
ture throughout the lung in allergic mice, which was not ob-
vious at the protein level as a result of sensitivity limitations of 
the immunostaining. Sections were also counterstained with 
E-cadherin or SMA to ensure the presence of the epithelium 
and to distinguish airways and vessels. These data clearly show 
that Nogo gene and protein expression in the lung is altered 
during settings of acute allergic asthma-like responses and in 
identified a potential role for Nogo-A in pathogenesis of experi-
mental autoimmune encephalomyelitis, an animal model of   
human multiple sclerosis (Fontoura et al., 2004). The Nogo-B 
isoform  is  highly  expressed  in  vascular  smooth  muscle  cells,   
endothelial cells, and monocytes/macrophages, and in the con-
text of the vasculature, the loss of Nogo promotes vascular   
injury (Acevedo et al., 2004; Kritz et al., 2008; Yu et al., 2009). 
Therapeutic delivery of Nogo-B in both murine and porcine 
models of acute vascular injury reduces the extent of vascular 
growth and neointima formation (Kritz et al., 2008). In humans, 
Nogo-B levels are reduced in atherosclerotic tissue and aortic 
aneurysms, and this reduction may contribute to plaque for-
mation, destabilization, and vascular abnormalities (Pan et al., 
2007; Rodriguez-Feo et al., 2007). However, little is known 
about the in vivo expression of Nogo-B or its function outside 
the vasculature.
In the present work, we show that Nogo-B is highly   
expressed in mouse and human lung tissue, most strikingly in 
pulmonary airways. During allergic asthma-like inflammation 
in the lung, the levels of Nogo-B in epithelia and bronchiolar 
smooth muscle are reduced and the genetic loss of Nogo   
augments lung inflammation in a mouse model of antigen-
driven Th2 inflammation. Transgenic expression of Nogo-B 
in pulmonary epithelium reduces asthma-like inflammation 
via the expression of palate lung and nasal clone (PLUNC), 
an antiinflammatory protein exclusively expressed in the nasal 
cavity and upper airways. Thus, Nogo-B in epithelial cells is   
a newly described regulator of the extent of allergic Th2   
lung inflammation.
RESULTS
Nogo-B is highly expressed in the lung
To examine Nogo gene expression in vivo, mice harboring a 
LacZ reporter inserted into the Nogo gene locus (Nogo-A/B+/ 
mice) were used (Kim et al., 2003). Remarkably, Nogo-A/B 
gene expression is highly expressed in the lung (Fig. 1 A). As seen 
in Fig. 1 B (top), Nogo is expressed in airways (Fig. 1 B, labeled 
A) both in E-cadherin–positive epithelium and smooth muscle 
actin (SMA)–positive airway smooth muscle and blood vessels 
(Fig. 1 B, labeled V). The same pattern of Nogo protein ex-
pression was confirmed by immunohistochemical staining of 
C57BL6 WT lung sections with a Nogo-A/B–specific antibody 
(Fig. 1 B, bottom), using lung sections from Nogo-A/B/ mice 
to verify specificity of the Nogo-A/B antibody (Fig. 1 B, inset). 
Because Nogo-A/B/ mice lack both Nogo-A and –B, whole 
lung lysates were analyzed for relative levels of these isoforms 
(using brain as a control for Nogo-A and lysates from heart or 
lung endothelial cells for Nogo-B). As seen in Fig. 1 C, Nogo-B 
is the predominant isoform in the lung as Nogo-A was un-
detectable. Therefore, Nogo function in the lung is most likely 
attributable to the Nogo-B isoform.
Expression of Nogo is reduced in a mouse model of antigen-
driven Th2 inflammation and in human severe asthma
To investigate if Nogo expression changes in the lung during 
asthma pathogenesis, we used the well established OVA model JEM VOL. 207, November 22, 2010 
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was almost undetectable in BAL of both strains 
(Fig. 3 C). IgE levels were also analyzed in mice 
before and after aerosolized OVA challenge. Blood 
total  IgE  (not  depicted)  and  OVA-specific  IgE 
levels were identical in WT and KO mice after 
sensitization but before challenge; however, after 
the third aerosolized OVA challenge, OVA-specific 
IgE levels were elevated in KO mice (Fig. 3 D), 
suggesting that mice lacking Nogo-A/B have 
dysregulated effector responses in this model of 
antigen-driven Th2 inflammation.
To help address the temporal aspects of the 
role of Nogo limiting inflammation in this model, 
BAL cellularity was examined 24 h after a single challenge 
rather than after a 3-d challenge. Lung inflammation is signif-
icantly elevated in KO mice 24 h after a single challenge of 
aerosolized OVA as compared with WT (Fig. 3 E, total cells and 
eosinophils). Additionally, to determine effects of Nogo on 
the  resolution  of  lung  inflammation,  BAL  cellularity  was 
evaluated in mice 7 and 14 d after challenge. KO mice dis-
played enhanced inflammation that persists at least out to 7 d, 
compared with WT mice, and the inflammatory response in 
all mice was resolved by 14 d (Fig. 3 F); however, a few residual 
eosinophils were present in KO mice at the latest time point. 
Finally, to examine if Nogo is important for Th1 lung inflam-
mation, WT and KO mice were sensitized with CFA/OVA 
and then challenged with aerosolized OVA as described in 
Materials and methods. The loss of Nogo did not influence 
CFA-induced lung inflammation (Fig. S4).
Loss of Nogo-A/B in resident lung cells is responsible  
for enhanced asthma-like inflammation
Because Nogo-B is expressed in many cell types in the lung 
and inflammatory cells, we examined its function in the resi-
dent lung tissue (i.e., the structural cells) versus inflammatory 
cells via BM transplantation (BMT) experiments. BMT was 
a human asthmatic, and Nogo expression is affected differen-
tially in airways and vessels.
Nogo-A/B/ mice display enhanced asthma-like responses
To determine whether endogenous Nogo promotes or limits 
lung inflammation, WT and congenic Nogo-A/B/ mice 
(herein referred to as KO; Zheng et al., 2003) were OVA sen-
sitized and challenged. Under baseline conditions, lungs from 
nonallergic KO mice were virtually identical to WT mice as 
indexed by lung histology and the absence of mucus staining 
by PAS. However, lungs from allergic KO mice had increased 
levels of inflammatory cells, mucus production (Fig. 3 A; top 
and bottom), and indices of airway hyperreactivity (Fig. S3) 
compared with WT mice. To determine the extent of lung 
inflammation and cellular composition, bronchioalveolar   
lavage (BAL) fluid was collected and evaluated for total and 
differential cell counts. OVA-sensitized and challenged KO 
mice display a 60% increase in total cell infiltrates, which are 
predominantly eosinophils, whereas macrophages, lymphocytes, 
and neutrophils were comparable in number between WT 
and KO mice (Fig. 3 B). The increase in inflammation in KO 
mice was associated with higher levels of Th2 cytokines in BAL 
(IL-13, IL-4, and IL-5), whereas IFN- (a typical Th1 cytokine) 
Figure 1.  Nogo-B is highly expressed in the lung.  
(A) Whole-mount X-gal staining of Nogo-A/B KO LacZ mouse 
lung tissue. Blue indicates positive Nogo-A/B gene expres-
sion throughout the lobe. Bar, 0.5 mm. (B) X-gal–stained 
lung sections from Nogo-A/B+/ LacZ mice (top). Blue indi-
cates positive Nogo gene expression in epithelium and 
smooth muscle of airways (A), and endothelial and smooth 
muscle cells of vessels (V), as well as parenchymal cells.  
Also shown are lung sections from WT mice stained with 
Nogo-A/B antibody 1761 (bottom). Brown staining indicates 
positive Nogo protein expression, and specificity of antibody 
was confirmed with negative staining of Nogo-A/B KO lung 
section (inset). Sections were also labeled with anti–E cad-
herin (Ecad) or -SMA to delineate epithelium and smooth 
muscle, respectively. Bars: (top) 200 µm; (bottom) 100 µm. 
(C) Lysates were immunoblotted with a Nogo-A/B antibody. 
Brain lysate is as a positive control for Nogo-A. Heart and 
mouse lung endothelial cells (mlecs) are positive controls 
for Nogo-B. Lung lysate from Nogo-A/B KO mice is a nega-
tive control and hsp90 is a loading control.2598 Nogo-B inhibits Th2-mediated lung inflammation | Wright et al.
Figure 2.  Regulation of Nogo-B expression during asthma-like conditions in mice and human asthma. (A) Nogo-B protein levels were signifi-
cantly decreased in total lung lysates of OVA-sensitized and challenged (allergic) mice versus WT control (nonallergic) mice. Shown is a typical Western 
blot from six individual experiments. Nogo-B levels were quantified by densitometry and normalized to hsp90 (*, P < 0.05). Data are expressed as mean ± SEM.  
n = 4–7 mice per group. (B) Lung sections from representative small and large airways of untreated (control, a and b) and OVA-challenged (c and d)  
WT mice stained with Nogo-A/B antibody. Brown indicates positive Nogo-A/B in airway epithelium (arrowheads), smooth muscle and vessels (asterisk) of 
control mice, and the loss of Nogo immunoreactivity in epithelium and smooth muscle, but not vessels (*, c and d), of OVA-challenged mice. Bar, 100 µm. JEM VOL. 207, November 22, 2010 
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epithelium of allergic lungs (Fig. 4 C, d, arrowhead), whereas 
endogenous Nogo-B is decreased in airway epithelium of 
STG-allergic lungs (Fig. 4 C, e, arrowhead), which is consis-
tent with observations in WT allergic mice. This implies that 
the asthmatic-like milieu is responsible for the loss of endog-
enous airway epithelial Nogo gene expression, yet it is not 
sufficient to affect Nogo-B transgene expression which is 
under the control of the CCSP promoter. Allergic DTG mice 
displayed a marked reduction in total inflammatory cells in 
the tissue (Fig. 4 C, h) and BAL (Fig. 4 D), which was mainly 
reflective of eosinophil levels as compared with STG-allergic 
mice (Fig. 4, C [g] and D, respectively). Allergic DTG mice 
also generated lower levels of Th2 cytokines in their BAL, in-
cluding IL-13, IL-4, and IL-5 (Fig. 4 E), as well as lower levels of 
mucus production compared with allergic STG mice (Fig. 4 C, 
j and i, respectively), which is indicative of a reduced asthmatic 
response. In contrast, mice that inducibly express Nogo-B in vas-
cular endothelium using an endothelial-specific (VE-cadherin) 
Tet-regulated driver line displayed no differences in asthma-
like responses as compared with control mice (unpublished 
data). To exclusively conclude that Nogo-B in epithelium is 
functioning in the DTG mice during the effector phase of 
the response, adoptive transfer of OTII CD4+ Th2 cells into 
STG and DTG mice was conducted, followed by OVA chal-
lenge via aerosolization. DTG mice displayed an attenuated 
inflammatory response (in total BAL and lung histology) com-
pared with STG (Fig. 4 F). Collectively, these data show that 
transgenic replacement of Nogo-B into the lung epithelium 
during allergic Th2 inflammation attenuates the effector phase 
of this response.
Genome-wide arrays demonstrate that endogenous Nogo-B 
regulates the expression of the PLUNC gene
To help decipher a mechanism for how Nogo functions in 
the lung, a genome-wide microarray of naive WT and KO 
lungs was conducted. Among 40,000 genes investigated, only 
one gene other than Nogo-A/B was significantly altered using 
stringent criteria of gene selection. KO lungs displayed a 278-
fold decrease in PLUNC mRNA levels (Table S1). PLUNC, 
which is also referred to as SPLUNC1 or SPURT, is a mem-
ber of the bactericidal permeability–increasing (BPI) protein/
PLUNC superfamily, whose members are thought to have 
the ability to bind and transfer lipid through their lipid-binding 
domains (Yamashita et al., 2001; Di et al., 2003; Bingle et al., 
2004). The function of PLUNC proteins is unclear, but they 
are hypothesized to be involved in host defense mechanisms 
conducted by transferring BM from WT and KO mice into 
8-wk-old lethally irradiated KO and WT mice, respectively, as 
well as matching genotypes for controls, and allowing recon-
stitution for 8 wk. Mice were then OVA-sensitized and chal-
lenged as described and analyzed for levels of inflammation. 
Consistent  with  initial  observations,  KO  BM  transplanted 
into KO mice displayed enhanced asthma-like inflammation 
as compared with WT BM cells transplanted into WT mice 
(Fig. 3, G and H), whereas KO BM transplanted into WT 
mice resulted in similar levels of Th2 inflammation, as ob-
served in WT mice with WT BM. In contrast, WT BM trans-
planted into KO mice resulted in a marked increase in allergic 
inflammation similar to levels found in KO mice transplanted 
with KO BM. Therefore, these data suggest that Nogo is act-
ing predominantly within the structural cells resident in the 
host lung tissue to attenuate asthma-like inflammation.
Transgenic Nogo-B expression in lung epithelium attenuates 
asthma-like inflammation
To examine whether the loss of Nogo-B in epithelial cells in-
fluences the extent of allergic Th2 responses, tetracycline (TET)-
inducible cell-specific Nogo-B transgenic mice were generated 
via  breeding  a  pTet  splice–TRE-hNogo-B-hemagglutinin 
(HA)–tagged mouse to a (TET-ON) Clara cell secretory pro-
tein (CCSP) promoter driver line (Tichelaar et al., 2000) to 
create CCSP-Nogo-B double transgenic (DTG) mice. DTG 
mice were put on doxycycline over several days and evaluated 
for expression of the transgene. Nogo-B HA is expressed in a 
time-dependent manner with a maximum expression after 7 d 
in lung lysates (Fig. 4 A) and the transgene localizes to the 
large airway epithelium (Fig. 4 B). Because these mice were 
used exclusively as an ON system, STG mice served as a con-
trol group for subsequent experiments.
Next, we tested whether transgenic expression of Nogo-B 
into the airway epithelium would rescue the loss of Nogo 
after OVA challenge and/or alter the extent of asthma-like 
inflammation. Both STG and DTG mice were placed on 
doxycycline water for 2 wk before OVA sensitization to sta-
bilize transgene expression. Mice were then subjected to OVA 
sensitization and challenge and evaluated for allergic asthma-
like response parameters. First, proper induction of Nogo-B 
transgene  expression  was  established  with  the  presence  of 
HA-tagged  transgene  in  airway  epithelium  of  nonallergic 
DTG lungs (Fig. 4 C, b, arrowhead), which was absent in 
nonallergic STG lungs (Fig. 4 C, a, arrowhead). Importantly, 
Nogo-B transgene expression was preserved in the airway 
The graph on the right depicts quantification of Nogo-A/B staining with multiple sections from multiple mice using the scoring system, where 3 is 100% 
positive staining and 0 is an absence of staining (*, P < 0.01). Data are expressed as the mean ± SEM. n = 4–8 mice for both groups and data are repre-
sentative of three experiments. Serial sections were stained with E-cadherin (e and f), H&E (g and h), and PAS (i and j). (C) Representative images of large 
(a and b) and small (c and d) airways from human lung sections of normal and fatal asthmatic specimens stained for Nogo with the N-18 antibody. 
Airway epithelium is indicated with arrowheads and vessels with asterisks. Bars: (top) 200 µm; (bottom) 100 µm. Images are representative of four individual 
normal human lung specimens and one individual fatal asthmatic specimen, with additional patient samples in Fig. S2. (D) Lung sections from control 
(top) and OVA-treated (bottom) Nogo-A/B+/ LacZ mice stained for -gal. Airways (both E-cadherin and SMA positive) are indicated with A and vessels 
(SMA positive only) are indicated with V. Bars, 100 µm. Images represent results obtained from three individual experiments where n = 6 mice.
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Figure 3.  Nogo-A/B KO mice display exaggerated antigen-driven Th2 inflammatory responses. (A) Representative lung sections from allergic 
WT and Nogo-A/B KO (KO). (B) Total and differential cell counts in BAL fluid from WT and KO control and OVA-challenged mice (*, P < 0.01). (C) Levels of 
Th2 cytokines IL-13, IL-4, and IL-5 and IFN- as a Th1 cytokine for control were measured in BAL of WT and KO OVA mice (*, P < 0.05). (D) Levels of OVA- 
specific IgE in serum of WT and KO control mice and in OVA mice before (sensitized only) and after challenge (*, P = 0.013). (E) Total cells and eosinophils 
were measured in BAL of allergic WT and KO mice as described in Results. *, statistically significant from WT mice. (F) 7 and 14 d after 3-d challenge  
(*, P < 0.05). (G and H) Lung histology (G) and cell counts (H) in BAL in OVA-challenged BMT mice (*, P < 0.05). Data are expressed as the mean ± SEM. 
 n = 4–8 mice for all groups representative of four individual experiments. Bars, 100 µm.JEM VOL. 207, November 22, 2010 
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qRT-PCR  (Fig.  5  A).  As  previously  reported,  PLUNC 
mRNA levels in tissue were reduced after OVA challenge in 
WT mice (Chu et al., 2007) and PLUNC gene expression 
was even further decreased in lungs from OVA-challenged 
KO mice (Fig. 5 B). The basal reduction of PLUNC protein 
was also observed in the BAL of KO mice as compared with 
WT mice (Fig. 5 C), whereas PLUNC levels were increased 
in naive CCSP-Nogo-B DTG mice compared with STG 
through their BPI-related N-terminal domain (Sung et al., 
2002). Most recently, PLUNC has been shown to exhibit anti-
inflammatory functions (Chu et al., 2007). Differences in 
PLUNC mRNA levels were confirmed by quantitative (q) 
RT-PCR to be significantly decreased in KO lungs by 95%, 
whereas two other microarray targets close to significance, 
TFF2 and Reg3, which were decreased by three- and five-
fold in KO lungs, respectively, did not display differences by 
Figure 4.  Transgenic expression of Nogo-B in lung epithelium inhibits allergic Th2 inflammation. (A) CCSP-Nogo-DTG mice were put on doxy-
cycline water (0.5 mg/ml) for different time points and the levels of Nogo-B HA–tagged transgene assessed. Endogenous mouse Nogo-B and hsp90 levels 
were used as loading controls. Each lane represents lung lysate from an individual mouse and was repeated one additional time. (B) Transgene expression 
in lung sections from CCSP-Ng-DTG mice. Bars, 100 µm. (C) CCSP-Ng-STG and DTG littermates were put on doxycycline water for 7 d before OVA sensiti-
zation/challenge. Lung sections from control and OVA-sensitized and challenged STG and DTG mice were stained for transgene expression (a and b, and  
c and d, respectively), Nogo-A/B (e and f), H&E (g and h), and PAS (I and j). Arrowheads highlight airway epithelium. Bar, 200 µm. (D and E) BAL cell counts 
(D) and levels of cytokines (E) were evaluated from BAL of OVA STG and DTG mice (*, P < 0.05). (F) WT OTII CD4+ Th2 cells were purified and adoptively 
transferred into STG and DTG mice, followed by OVA challenge and evaluation of total levels of inflammation in the BAL (*, P < 0.05). Data are expressed 
as the mean ± SEM. n = 5–8 mice for both groups representative of three individual experiments.2602 Nogo-B inhibits Th2-mediated lung inflammation | Wright et al.
change with OVA 
challenge (Fig. 6 B, 
compare  lanes  3, 
4,  7,  and  8).  As 
shown before, en-
dogenous  mouse 
PLUNCs  are  re-
duced by OVA in WT mice (Fig. 6 B, lanes 2 and 4) and re-
mained greatly reduced in PTG-KO mice compared with 
PTG. Interestingly, transgenic expression of PLUNC in Nogo 
KO mice greatly diminished lung inflammation (Fig. 6 C) 
and total inflammatory cells in their BAL (Fig. 6 D). These 
data demonstrate that the loss of PLUNC in Nogo-deficient 
mice may explain, in part, the enhanced lung inflammation in 
this strain of mice because transgenic rescue of PLUNC nor-
malizes the Nogo KO phenotype.
DISCUSSION
Our results show an unanticipated role of Nogo-B in the 
lung where it serves a prominent role in the host defense sys-
tem and controls the extent of Th2-mediated asthma and 
asthma-like inflammation and disease progression. While ex-
ploring potential mechanisms of Nogo function, microarray 
results identified a single gene markedly down-regulated in 
lung extracts from Nogo KO mice: PLUNC. Indeed, Nogo 
regulation of PLUNC gene expression participates in Th2-
driven lung inflammation because PLUNC levels in BAL 
fluid are reduced in Nogo KO mice and elevated in epithelial-
specific Nogo-B transgenic mice. Genetic epistasis experiments 
demonstrate that transgenic reexpression of PLUNC in a 
Nogo-deficient background partially rescues lung inflamma-
tion, demonstrating the causal link between the loss of Nogo 
and PLUNC and enhanced inflammation.
There are now several studies describing Nogo family 
members as either negative or positive regulators of disease 
pathogenesis. In models of nerve regeneration or dysfunction 
control mice (Fig. 5 D). To directly link Nogo-B to the ex-
pression of PLUNC, Nogo-B levels were reduced in normal 
human bronchial epithelial cells (NHBECs) using siRNA, 
and  PLUNC  mRNA  levels  were  evaluated. As  expected, 
Nogo-B siRNA reduced Nogo protein levels by 80–90% and 
lowered PLUNC mRNA levels by 60% (Fig. 5 E). The de-
crease in PLUNC mRNA levels after Nogo-B silencing was 
specific because the mRNA levels of TGF-1 and IL-4R 
were unchanged.
The transgenic expression of PLUNC into lung epithelium 
rescues enhanced asthma-like response in Nogo-A/B/ mice
CCSP-PLUNC transgenic mice (PTG), which constitutively 
express the human form of PLUNC specifically in lung epi-
thelium, were generated (unpublished data). PTG mice were 
then bred onto the Nogo-A/B/ background to achieve 
PTG-KO mice and evaluated for transgene expression and 
localization. Endogenous PLUNC expression was detected 
exclusively in epithelial cells lining the trachea (Fig. 6 A, top 
left) and the upper parts of the main bronchi of WT mice, 
whereas PLUNC was detected to a lesser extent in corre-
sponding lung epithelium of KO mice (Fig. 6 A, top right). 
These findings are consistent with reduced PLUNC levels in 
BAL of KO mice (Fig. 6 B). Transgenic PLUNC was present 
in epithelial cells of the trachea (Fig. 6 A, bottom left) and 
upper part of the large bronchi as indicated by the enhanced 
expression of PLUNC staining in PTG and PTG-KO mice. 
Transgenic PLUNC was also present in epithelium of small 
airways of PTG and PTG-KO (Fig. 6 A, insets) where endog-
enous PLUNC is not normally expressed. As seen in Fig. 6 B, 
transgenic human PLUNC protein expression was detected 
from endogenous mouse levels as they migrate differently on 
SDS-PAGE gel and are detected by species-specific antibod-
ies. Transgenic human PLUNC expression runs faster than 
murine PLUNC on SDS PAGE, is detected at similar levels 
in the BAL fluid of PTG and PTG-KO mice, and does not 
Figure 5.  Nogo regulates Plunc expres-
sion in vivo and in vitro. (A) Levels of basal 
gene expression (PLUNC, Tff2, Reg3, 
IL13R1, IL13R2, and amcase) in WT and 
Nogo-A/B KO (KO) lungs were determined  
by qRT-PCR. Data were expressed relative to 
WT gene expression of 100% (*, P < 0.01).  
(B) PLUNC gene expression in lungs from 
control and allergic mice. Data are expressed 
relative to WT control gene expression of 
100% (*, P < 0.01). (C and D) Basal levels of 
PLUNC protein were analyzed in BAL of WT 
and Nogo-A/B/ mice (C) and in BAL of 
CCSP-Ng-STG and –DTG mice (D) put on doxy-
cycline water for 3 mo using a PLUNC anti-
body. Ponceau-stained band at 150 Kb was 
used as a loading control. (E) NHBECs were 
treated with a nonsilencing (NS) siRNA or 
siRNA specifically targeting Nogo-B for 72 h 
and evaluated for gene expression of Nogo-B, 
Plunc, TGF-, and IL4R by qRT-PCR. Data 
were expressed relative to NS gene expression 
of 100% (*, P < 0.01). Data are expressed as 
the mean ± SEM. n = 3–6 mice for all groups 
representative of three experiments with each 
sample run in triplicate.JEM VOL. 207, November 22, 2010 
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decreases in airway epithelium and smooth muscle yet in-
creases in the pulmonary vasculature. These cell type–specific 
changes of Nogo gene expression are most likely a result of 
local factors (inflammatory cytokines, particularly the Th2 
cytokines IL-13 and IL-4) in the asthmatic-like milieu. In ad-
dition, the genetic loss of Nogo enhances the magnitude of 
Th2-driven allergic inflammation, in part by controlling the 
expression of the airway epithelial antiinflammatory protein 
PLUNC. Therefore, the importance or relevance of changes 
in Nogo expression in certain cell types may depend on the 
disease environment and nature of the inflammatory response. 
Although Nogo-B is ubiquitously expressed, the differential 
regulation of Nogo expression in alternate cell types high-
lights the idea that Nogo may exert varying functions in each 
cell type even within the same disease paradigm. With respect 
to how the Nogo gene is regulated, there has been a single 
extensive study on the Nogo-A/B promoter (Oertle et al., 
2003); however, the regulation of Nogo expression in indi-
vidual cells types has not yet been systematically evaluated. 
Whether the changes in Nogo-B expression are consequences 
of the asthmatic-like response or causal to disease progression 
is not entirely clear. Yet, when Nogo-B is reconstituted back 
in the CNS (Yang and Strittmatter, 2007) and after vascular 
injury (Acevedo et al., 2004; Paszkowiak et al., 2007), Nogo-A 
and Nogo-B, respectively, may serve independent inhibi-
tory functions and the inhibitory role of Nogo-A appears to 
be model dependent. In regeneration models, Nogo-A or 
fragments of Nogo-A are presumably released from damaged 
myelin  to  dampens  axonal  growth.  In  the  vascular  injury 
models, endogenous Nogo-B gene expression is reduced in 
the inflamed vessel and reintroduction of Nogo-B rescues this 
phenotype by promoting endothelial cell migration and re-
duces smooth muscle cell proliferation and migration (Acevedo 
et al., 2004; Kritz et al., 2008). However, in models of wound 
healing and tissue ischemia, endogenous Nogo-B participates 
in the extent of recovery, largely via regulation of macrophage 
motility and gene expression (Yu et al., 2009). Thus, it appears 
that  Nogo  isoforms  exert  diverse  actions  in  multiple  cell 
types, and the differences in function are likely attributable to 
the intracellular role of the RTN domain versus the biologi-
cally active fragments generated upon tissue damage. Clearly, 
in the model of Th2 lung inflammation in the present study, 
Nogo-B exerts cell restricted actions within the epithelium. 
During the evolution of Th2 inflammation, Nogo-B expression 
Figure 6.  Transgenic expression of PLUNC in lungs of Nogo-A/B KO mice reduces allergic Th2 inflammation. (A) Lung sections from WT, KO, 
PLUNC transgenic (PTG)–WT, and PTG-KO were stained for PLUNC. Endogenous PLUNC (only in the trachea and upper airways) was observed in tracheal 
epithelium of WT and, to a lesser extent, in KO (top). Transgenic PLUNC was observed in epithelium of upper airways (bottom) as well as further down the 
smaller airways (insets) in both WT and KO backgrounds. (B) BAL from WT, PTG-WT, KO, and PTG-KO mice with and without OVA challenge were immuno-
blotted for levels of endogenous PLUNC (mPLUNC at 25 kD) and transgenic PLUNC (hPLUNC at 20 kD) protein expression. Each lane of the Western blot 
represents lung lysate from typical individual mouse and was observed in n = 4–8 mice for each group. (C and D) Lung H&E staining (C) and total and differ-
ential BAL cell counts (D) of KO and PTG-KO mice challenged with OVA (*, P < 0.05; **, P < 0.01). Bars, 200 µm. Data are expressed as the mean ± SEM.  
n = 6 mice for both groups representative of two experiments.2604 Nogo-B inhibits Th2-mediated lung inflammation | Wright et al.
loss or gain of Nogo function in the epithelium in vivo regu-
lates PLUNC levels and, more directly, siRNA-mediated re-
duction of Nogo-B in cultured epithelial cells also reduces 
PLUNC mRNA levels, recapitulating the microarray dataset. 
Interestingly, these in vitro experiments require the intracel-
lular function of Nogo in ER (Voeltz et al., 2006; Shibata et al., 
2008), and perhaps by maintaining the integrity of the reticu-
lar ER Nogo-B regulates aspects of ER stress and/or tran-
scriptional control of the PLUNC gene. It is appreciated that 
ER stress is a component of asthma and other chronic inflam-
matory diseases (Cantero-Recasens et al., 2010), and the con-
temporaneous regulation of PLUNC by Nogo-B is striking 
and a novel area of exploration.
Thus, Nogo-B in the lung serves a major role in the air-
way epithelium as an inhibitor of antigen-driven Th2 inflam-
mation as supported by genetic loss and gain of function 
approaches. Further elucidation of the mechanisms underly-
ing the interplay between Nogo and PLUNC affords new 
insights into the complex role of RTNs and offers great po-
tential for revealing opportunities for therapeutics that modu-
late the inflammatory response in a range of diseases.
MATERIALS AND METHODS
Mice
Nogo-A/B/  and  Nogo-A/B/  LacZ  mice. Nogo-A/B/ mice 
were provided by M. Tessier-Levigne (Genentech, South San Francisco, CA; 
Zheng et al., 2003). Nogo-A/B/ LacZ gene reporter mice were provided 
by S, Strittmatter (Yale University, New Haven, CT; Kim et al., 2003). Both 
strains were crossed onto a C57BL6 background for >10 generations and 
used at 6–8 wk of age for these studies.
CCSP-Nogo-B transgenic mice. A transgene encoding ptet-splice-TRE 
(tetracycline responsive element), followed by HA-tagged human Nogo-B, 
was used to generate NogoB TG reporter mice. These mice were bred to 
lung epithelial CCSP driver mice (J. Whitsett, Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH; Tichelaar et al., 2000), which use the Clara 
cell  10-kD  protein  (CC10)  promoter  to  express  the  reverse  tetracycline 
transactivator using a Tet-On system to achieve DTG positive for both CCSP 
and NogoB TG mice (DTG) and single transgenic positive for either CCSP 
or NogoB TG mice (STG). Mice were bred onto a C57BL/6 background for 
>10 generations, and littermates were used in these studies.
CCSP-PLUNC transgenic Nogo-A/B/ mice. CCSP-PLUNC trans-
genic positive mice (PTG; P. Di, University of Pittsburgh, Pittsburgh, PA) 
contain  the  transgenes  for  the  CC10  promoter  driver  and  the  human 
PLUNC gene for constitutive expression in Clara cells. PTG mice were bred 
to Nogo-A/B KO mice to obtain PTG-KO mice and littermate KO mice 
were used as controls.
Doxycycline water administration. 6-wk-old DTG mice and STG lit-
termate controls were given 0.5 mg/ml doxycycline in their drinking water 
for 2 wk before experiments were conducted as previously described (Ray 
et al., 1997; Fontoura et al., 2004). All animal experiments were approved by 
the Yale School of Medicine Institutional Animal Care and Use Committee 
in accordance with federal guidelines.
OVA/Alum sensitization and challenge
OVA sensitization and challenge was accomplished using modifications of 
the protocols previously described by Wang et al. (2000). In brief, mice 6–8 wk 
of age were immunized with 10 µg of chicken OVA fraction V (Sigma- 
Aldrich) in a 2% ALUM suspension by i.p. injection on days 0 and 5. On days 
12, 13, and 14, mice were challenged for 30 min with an aerosol of 1% OVA 
into the lung epithelium using tissue-specific transgenic mice, 
this is sufficient to reduce Th2-driven inflammation. This sug-
gests that the loss of Nogo in the epithelium during asthma 
pathogenesis contributes to this disease. The importance of 
cell specificity of Nogo-B function is exemplified by the lack 
of effect of endothelial Nogo-B expression on the asthmatic-
like response.
One aspect of murine asthma-like responses that have 
been extensively studied is the importance of CD4+ Th2 cells 
and cytokines, which is a hallmark of asthma pathogenesis 
(Cohn et al., 2004). Although Nogo-B is found in inflamma-
tory cells (Yu et al., 2009), BMT experiments clearly show 
that the major role for Nogo-B exists in the tissue and not the 
BM-derived cells. OVA-specific IgE levels were similar in 
WT and Nogo KO mice after sensitization, implying that loss 
of Nogo-A/B does not alter the sensitization process, devel-
opment of antigen-specific memory responses, and IgE class 
switching. It is only after aerosolized OVA challenge that a 
difference in OVA-specific IgE is detected in Nogo KO mice, 
supporting the idea that Nogo-B regulates aspects of the ef-
fector phase but not priming/sensitization phases of the asth-
matic response. Upon further dissection of the time course of 
inflammation in Nogo KO mice, enhanced Th2 lung inflam-
mation occurs as early as 24 h after allergen challenge. There-
fore, Nogo-B inhibitory function is involved in the very early 
phase of Th2-mediated lung inflammation, and without it the 
environment is staged for an enhanced and prolonged inflam-
matory response. This is evident in Nogo KOs, which display 
increased lung inflammation 7 d after challenge and residual 
eosinophils even 14 d after challenge.
It is apparent that the airway epithelium plays a major role 
in the phenotype observed in Nogo KO mice. The airway 
epithelium functions not only as a protective barrier but also 
orchestrates aspects of the inflammatory response including 
the production of chemokines (Holgate, 2007). Using an un-
biased microarray approach to monitor gene expression in 
lungs from naive WT and Nogo KO mice reveals a remark-
able decrease in PLUNC gene expression, a result confirmed 
at the protein level in vivo. PLUNC has recently been de-
scribed as an antibacterial antiinflammatory protein that is 
specifically expressed and secreted by epithelial cells of the 
upper airways and nasal cavity (Chu et al., 2007). Therefore, 
Nogo KO mice, which express low levels of PLUNC, may 
have impaired airway barrier protection causing these mice to 
become more susceptible to lung insults such as allergic Th2 
inflammation. Any  compromise  of  epithelial  integrity  can 
create a vulnerability to inhaled substances and susceptibility 
to activation of inflammatory responses (Holgate, 2007). Thus, 
the role for Nogo in the airway epithelium could certainly be 
expanded to other diseases of the lung that are generated 
through this route of entry.
Exactly how Nogo regulates PLUNC gene expression is 
not yet known; however, there is a direct correlation between 
Nogo levels and PLUNC expression and this coincides with 
the extent of lung inflammation. Evidence for a causal link 
between these genes are experiments showing that the genetic JEM VOL. 207, November 22, 2010 
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mouse and human PLUNC antibodies (R&D Systems). Secondary antibodies 
were fluorophore conjugated (LI-COR Biosciences). Bands were visualized 
using the Odyssey Infrared Imaging System (LI-COR Biosciences).
BAL
Lung inflammation was assessed in BAL as described previously with slight 
modification (Wang et al., 2000; Kang et al., 2007). In brief, trachea was can-
nulated and lung was lavaged twice with 0.8 ml PBS, pooled, and centrifuged 
for each animal. Supernatant was stored at 80°C for later analysis of cyto-
kines by ELISA. Pelleted cells were evaluated for total cell counts using a he-
macytometer. For differentials, 5 × 104 cells were aliquoted for cytospin and 
spun at 14,000 rpm for 5 min and stained with Diff-Quick (Thermo Fisher 
Scientific). The number and type of cells in the cell pellet were determined 
with light microscopy.
Cytokine detection assays
Cytokine levels were analyzed from BAL by ELISA (R&D Systems) for   
IL-13, IL-4, IL-5, and IFN-.
IgE
Blood was collected by eye bleeds before OVA challenge and by cardiac 
puncture for after OVA challenge. Blood clots were removed and blood was 
spun down to separate serum. Serum levels of total and OVA-specific IgE 
were determined by ELISA, as per the manufacturer’s instructions.
BMT
BMTs were conducted as previously reported by our laboratory (Fernández-
Hernando et al., 2007). In brief, Nogo-A/B KO or WT mice 6–8 wk old 
were lethally irradiated with 1,000 rads (10 Gy) from a cesium source 4 h 
before transplantation. BM was collected from femurs of donor Nogo-A/B 
KO or WT mice by flushing with sterile medium (RPMI 1640, 2% FBS,   
5 U/ml heparin, 50 U/ml penicillin, and 50 mg/ml streptomycin). Recipient 
mice were injected with 2 × 106 BM cells through the jugular vein. 4 wk   
after BMT, peripheral blood was collected for PCR analysis of BM reconsti-
tution. 8 wk after BMT, mice were fully chimeric and subjected to OVA 
model of asthma.
Microarray
Whole lung tissue RNA from 8-wk-old naive WT and Nogo-A/B KO mice 
(Genentech) was isolated using a hybrid Trizol/QIAGEN protocol of RNA 
isolation. High purity of RNA was confirmed by spectrophotometric mea-
surements and RNA agarose gel electrophoresis. RNA samples from three 
biological replicates of each group were hybridized to whole genome mouse 
arrays (Agilent Technologies). Sample preparation, labeling, and array hybrid-
izations were performed according to standard protocols from the University 
of California, San Francisco Shared Microarray Core Facilities and Agilent 
Technologies. A linear model was fit to the comparison to estimate the mean 
M values and calculated moderated t statistic, B statistic, false discovery rate, 
and p-value for each gene for the comparison of interest. Adjusted p-values 
were produced by the method proposed by Holm (1979). All procedures 
were  performed  using  functions  in  the  R  package  limma  in  Bioconductor 
(Gentleman et al., 2004).
qRT-PCR
Total RNA was extracted from homogenized lungs using Trizol (Invitrogen), 
followed by further purification with RNeasy columns (QIAGEN). Reverse 
transcription was performed on RNA using the TaqMan reverse transcrip-
tion kit (Applied Biosystems). Equal amounts of cDNA were prepared with 
Sybr Green MasterMix (Bio-Rad Laboratories) and primers designed for 
genes of interest and run on an iCycler machine (Bio-Rad Laboratories). 
Data were normalized to 18s levels and expressed relative to control.
NHBEC cultures and siRNA treatment
NHBECs (Lonza) were cultured according to manufacturer’s instructions. 
At 60% confluency, cells were treated with siRNA nonsilencing control 
(QIAGEN) or siRNA against human Nogo-B gene (QIAGEN) precomplexed 
in endotoxin-free PBS using a compressor nebulizer (Comp Air Elite NE-
C21V; OMRON). Mice were sacrificed 24 h after the last challenge. Control 
mice were given PBS in place of OVA in the i.p. sensitization and/or chal-
lenge stages of the protocol.
Adoptive transfer of OTII CD4+ Th2 cells
CD4 T cells from OT-II mice transgenic for OVA-specific TCR were iso-
lated and polarized in vitro to TH2 cells as previously described by our labo-
ratories (Niu et al., 2007). Cultured Th2-like cells were harvested after 4 d 
and 2 × 106 cells were injected i.v. into syngeneic recipients. 1 d after transfer 
of cells, mice were challenged with 1% OVA aerosol in endotoxin-free PBS 
for a total of 7 d and sacrificed 24 h after the last challenge.
Tissue isolation and histology
As described previously by our laboratories (Wang et al., 2000), animals were 
anesthetized, a median sternotomy was performed, and right heart perfusion 
was accomplished with calcium and magnesium-free PBS. The right lung was 
either collected immediately for protein or RNA isolation or frozen in liquid 
nitrogen and stored at 80°C until later use. The heart and lungs were re-
moved en bloc, inflated at 25-cm pressure with 0.5% low melting point aga-
rose, fixed, paraffin embedded, sectioned, and stained. Stains for hematoxylin 
and eosin (H&E) and PAS for mucus were performed by the Research His-
tology Laboratory, Department of Pathology, at the  Yale University School 
of Medicine.
Human lung tissue specimens
Five  human  lung  tissue  samples  were  obtained  under  the  guidance  of   
Dr. Robert Homer from the  Yale Center for Asthma and Airways Disease tissue 
bank. Four of these tissue specimens considered to be nonasthmatic were ac-
quired from excess tissue resected during surgical procedures. One individual 
tissue sample was acquired from lung tissue of a fatal asthmatic. All specimens 
were paraffin embedded and tissue processed using standard clinical tech-
niques by Yale Pathology guidelines. Sections were cut at 5-µm thickness 
onto positively charged slides.
Immunohistochemistry
For immunodetection of proteins, sections were rehydrated, blocked with   
3% H2O2, and antigen retrieval was performed. Sections were blocked and 
permeabilized in 10% donkey serum, 0.5% BSA, and 0.1% Triton X-100. 
Primary antibodies used were: -SMA (Dako), high-affinity HA antibody 
(Roche),  E-cadherin  (Invitrogen),  Nogo-A/B  using  Nogo1761  antibody   
serum designed by our laboratory against aa 17–61 (Imgenex), and biotin-
conjugated human PLUNC antibody (R&D Systems). Secondary antibodies 
included biotin-conjugated anti–rabbit, –mouse, and –goat (Jackson Immuno-
research  Laboratories).  Counterstaining  was  performed  using  Mayer’s   
hematoxylin. Images were taken with a light microscope (Eclipse 80i;   
Nikon). Nogo-A/B staining was quantified using a scoring system, where 3 
was 100% staining and 0 was an absence of staining as determined by a 
blinded observer.
X-gal staining
Lungs were fixed in buffer (1% formalin, 0.002% glutaraldehyde, and 0.0002% 
NP-40 in PBS, pH 7.4-7.6) for 10 min at room temperature. Lungs were 
stained with X-gal buffer (1 mg/ml X-gal in DMSO [American Bioanalytical], 
5 mM K-ferricyanide, 5 mM K-ferrocyanide, 2 mM MgCl2, and 0.02% 
NP-40) and developed at 37°C overnight. WT lungs were treated equiva-
lently as control. Lungs were paraffin embedded and cut in 10-µm sections. 
Slides were deparaffinized, rehydrated, and counterstained with nuclear fast 
red (TACS). Images were taken with a light microscope.
Protein isolation and immunoblot analysis
Proteins from lung tissue and cell lysates were resolved by SDS/PAGE and im-
munoblotting as described previously by our laboratory (Suárez et al., 2008). 
Primary antibodies used were Nogo1761 antibody, as described in Immuno-
histochemistry,  Hsp90  (Santa  Cruz  Biotechnology,  Inc.),  and  biotinylated 2606 Nogo-B inhibits Th2-mediated lung inflammation | Wright et al.
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Statistics
Normally distributed data are expressed as SEM and assessed for significance 
between groups by two-tailed Student’s t test or two-way ANOVA with 
Bonferroni correction for multiple comparisons when appropriate. Values of 
P < 0.05 were considered statistically significant and are representative of 
evaluations in a minimum of six mice.
Pulmonary function test
The baseline resistance and AHR in unrestrained conscious animals were assessed 
by barometric plethysmography using whole-body plethysmography (Buxco 
Electronics) as described by our laboratory (Zhu et al., 1999). In brief, mice 
were placed into whole-body plethysmographs and interfaced with comput-
ers using differential pressure transducers. Measurements were made of respi-
ratory rate, tidal volume, and enhanced pause. Airways resistance is expressed 
as Penh = [(te/0.3 tr)  1] × (2 Pef/3 Pif), where Penh = enhanced pause, te = expi-
ratory time (in seconds), tr = relaxation time (in seconds), Pef = peak expira-
tory flow (in milliliters), and Pif = peak inspiratory flow (in milliliters per 
second). Increasing doses of methacholine were administered by nebulization for 
2 min, and Penh was calculated over the subsequent 5 min.
OVA/CFA sensitization and challenge
OVA sensitization and challenge was accomplished using modifications of 
the protocols as previously described (Cohn et al., 1997; Yip et al., 1999).   
In brief, mice 6–8 wk of age were immunized with an emulsion of chicken 
OVA fraction V (10 µg; Sigma-Aldrich) in CFA by s.c. injection along each 
flank on day 0. On days 12, 13, and 14, mice were challenged for 30 min with 
an aerosol of 1% OVA in endotoxin-free PBS using a compressor nebulizer 
(Comp Air Elite NE-C21V). Mice were sacrificed 24 h after the last chal-
lenge. Control mice were given PBS in place of OVA in the i.p. sensitization 
and/or challenge stages of the protocol.
Online supplemental material
Fig. S1 demonstrates that Nogo-A is undetectable in lysates prepared from 
naive or sensitized and challenged lungs. Fig. S2 shows the loss of immuno-
reactive Nogo-B in lung sections from three additional fatal asthmatic speci-
mens.  Fig.  S3  depicts  increased  airway  hyperreactivity  in  sensitized  and 
challenged Nogo-A/B KO mice compared with littermate controls. Fig. S4 
documents that Th1-driven lung inflammation in Nogo-A/B KO mice does 
not differ from control mice. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20100786/DC1.
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